{
    "clinical_study": {
        "@rank": "3231", 
        "arm_group": [
            {
                "arm_group_label": "Lesinurad and Tums", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: 240 mL water or  240 mL water and Tums Day 2: Lesinurad 400 mg or  Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg"
            }, 
            {
                "arm_group_label": "Lesinurad and MINTOX", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the potential effects of calcium carbonate and aluminum/magnesium\n      hydroxide-containing antacids on the pharmacokinetics (PK) and pharmacodynamics (PD) of\n      lesinurad in healthy, adult male subjects."
        }, 
        "brief_title": "Antacid Interaction Study", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "In this study, lesinurad and antacid will be administered in the fed state, antacid doses\n      will be attenuated to reflect the more commonly used doses, baseline PD assessments will be\n      performed both in presence and absence of antacid treatment, and the sequence of treatments\n      (lesinurad +/- antacid) will be randomized."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a body weight \u2265 50 kg (110 lbs) and body mass index \u2265 18 and \u2264 30 kg/m2.\n\n          -  Subject is free of any clinically significant disease or medical condition, per the\n             Investigator's judgment\n\n        Exclusion Criteria:\n\n          -  Subject has a history or suspicion of kidney stones.\n\n          -  Subject has undergone major surgery within 3 months prior to Screening.\n\n          -  Subject donated blood or experienced significant blood loss (>450 mL) within 12 weeks\n             prior to Screening or gave a plasma donation within 4 weeks prior to Screening.\n\n          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982201", 
            "org_study_id": "RDEA594-130"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lesinurad and Tums", 
                    "Lesinurad and MINTOX"
                ], 
                "intervention_name": "Lesinurad 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lesinurad and Tums", 
                "intervention_name": "Tums 500 mg and 750 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lesinurad and MINTOX", 
                "intervention_name": "MINTOX 10 mL", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antacids", 
                "Aluminum hydroxide, magnesium hydroxide, drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kalamazoo", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "49007"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interaction Between Lesinurad and Calcium Carbonate and Aluminum/Magnesium Hydroxide-Containing Antacids in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "J. Hall", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Plasma in terms of maximum observed concentration (Cmax), time of occurrence of maximum observed concentration (Tmax), area under the concentration-time curve (AUC), apparent terminal half-life (t\u00bd), renal clearance (CLR), and adverse event (Ae).", 
                "measure": "PK profile of lesinurad from plasma and urine", 
                "safety_issue": "No", 
                "time_frame": "Day 2 and Day 7"
            }, 
            {
                "description": "Serum PD in terms of serum urate concentration, urine uric acid excretion amount, renal clearance of uric acid, and fractional excretion of uric acid.", 
                "measure": "PD profile of Lesinurad  from serum and urine", 
                "safety_issue": "No", 
                "time_frame": "Day 2 and Day 7"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982201"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters", 
            "safety_issue": "Yes", 
            "time_frame": "5 weeks"
        }, 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}